Alexandria Hellmich
Family · Mobile, ALNPI 1386147247
Payments from drug & device makers
Across 636 payments — averaging $19.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Novo Nordisk$2K
- Lilly USA, LLC$2K
- AstraZeneca$497
- Bayer$474
- Sanofi-aventis U.S. LLC$465
- plus $4K from 31 others
What the payments were for
- Consulting fees$7806%
- Travel & lodging$1,57113%
- Food & beverage$10,17581%
- Education$390%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 70 | $3,318 |
| Novo Nordisk | 185 | $2,157 |
| Lilly USA, LLC | 87 | $1,598 |
| AstraZeneca(2 entities) | 23 | $497 |
| Bayer | 31 | $474 |
| Sanofi-aventis U.S. LLC | 18 | $465 |
| Boehringer Ingelheim | 22 | $442 |
| Abbott | 23 | $438 |
| Corcept Therapeutics | 22 | $370 |
| AbbVie | 19 | $357 |
| Amgen(2 entities) | 18 | $350 |
| Xeris Pharmaceuticals, Inc. | 17 | $340 |
| Dexcom, Inc. | 36 | $333 |
| Esperion Therapeutics, Inc. | 7 | $218 |
| BD | 8 | $187 |
| Novartis | 6 | $169 |
| Insulet Corporation | 6 | $155 |
| Rochester Medical Corporation | 4 | $85 |
| Lifescan, Inc. | 5 | $68 |
| Amneal Pharmaceuticals LLC | 4 | $65 |
| IBSA Pharma Inc. | 3 | $58 |
| Recordati_rare_diseases_inc. | 2 | $45 |
| Tandem Diabetes Care, Inc. | 2 | $38 |
| Mannkind Corporation | 2 | $35 |
| Antares Pharma, Inc. | 2 | $35 |
| Nevro Corp. | 1 | $33 |
| Kyowa Kirin, Inc. | 2 | $32 |
| Merck | 2 | $30 |
| Ascendis Pharma Endocrinology Inc | 1 | $30 |
| Amryt Pharma Holdings Ltd | 1 | $23 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| EUSA Pharma (US) LLC | 1 | $21 |
| Radius Health, Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $17 |
| Averitas Pharma Inc. | 1 | $15 |
| Pfizer | 1 | $15 |
| Impel Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INPEN SMART INSULIN DELIVERY SYSTEM$1,124
- MINIMED 770G$780
- InPen$441
- Ozempic$369
- MINIMED 780G$140
- FARXIGA$125
- NEXLIZET$125
- NEXLETOL$125
- EVENITY$122
- JARDIANCE$119
- TZIELD$104
How this compares
$12,565 in reported general payments places this provider in the 95th percentile of 3,415 family providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 535 | $681,257 |
| JardianceEmpagliflozin | 488 | $492,415 |
| MounjaroTirzepatide | 147 | $180,413 |
| TrulicityDulaglutide | 130 | $155,437 |
| FarxigaDapagliflozin Propanediol | 163 | $147,997 |
| Tresiba Flextouch U-200Insulin Degludec | 78 | $119,875 |
| Tresiba Flextouch U-100Insulin Degludec | 101 | $77,926 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 54 | $71,112 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 70 | $45,546 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 22 | $44,119 |
| Humalog Kwikpen U-100Insulin Lispro | 120 | $41,221 |
| FiaspInsulin Aspart (Niacinamide) | 15 | $23,174 |
| Humalog Kwikpen U-200Insulin Lispro | 16 | $19,281 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 118 | $18,127 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 94 | $17,845 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Rybelsus | $2,157 | $718,555563 claims |
| Boehringer IngelheimJardiance | $442 | $492,415488 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,598 | $340,006294 claims |
| AstraZenecaFarxiga | $497 | $147,997163 claims |
| AbbVieSynthroid | $357 | $1,76520 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $65 | $1,476133 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,415 family providers in Alabama.
Other family in Mobile
- Christopher LovellMobile$64K
- Sanjyot BhadkamkarMobile$16K
- Freda SmithMobile$14K
- Kara BoutwellMobile$12K
- Justin WilsonCullman$1.1M
- Leigh Ann ChildressHuntsville$240K
- Molly ReevesAuburn$158K
- Christina CanteyHuntsville$118K
- Leigh LunaMontgomery$69K
- Justin SimpsonTuscaloosa$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.